Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma (Q81631158)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

S Murali

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

E Winton

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

E K Waller

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

L T Heffner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

S Lonial

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

C Flowers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

J Kaufman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

M Arellano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

M J Lechowicz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

K P Mann

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

H J Khoury

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

A A Langston

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

14 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

529-534

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18622414%20AND%20SRC:MED&resulttype=core&format=json

Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.201

7 January 2021